Immunity for breakfast?

What if preventing millions of deaths in children every year were as simple as a little transgenic technology and a favorite food that's a dime a dozen, proverbially speaking? To Peter Lachmann, at the University of Cambridge in England, it might be just that straightforward. Related Articles Science Applied to the Greatest Needs Implementing Change Lab Transformation Lachmann is convinced that antibody-enriched egg whites may be the key

Written byIshani Ganguli
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

What if preventing millions of deaths in children every year were as simple as a little transgenic technology and a favorite food that's a dime a dozen, proverbially speaking? To Peter Lachmann, at the University of Cambridge in England, it might be just that straightforward.

Lachmann is convinced that antibody-enriched egg whites may be the key to wide-scale protection against diarrheal disease. The transgenic technology could be poised to deliver, thanks to the work of avian geneticists such as Helen Sang at the Roslin Institute in Scotland. But this clever recipe for passive immunity might take decades of prep time.

Each year, diarrheal diseases kill two million children under the age of five in the developing world. (Click here for related story.) Lachmann hopes that antibodies present in transgenic eggs would linger in the intestines of such children and coat the toxins produced by gut-living pathogens such as enterotoxic Escherichia ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies